Abstract:Protein methyltransferase (PMT)-mediated posttranslational modification of histone and nonhistone substrates modulates stability, localization, and interacting partners of target proteins in diverse cellular contexts. These events play critical roles in normal biological processes and are frequently deregulated in human diseases. In the course of identifying substrates of individual PMTs, bioorthogonal profiling of protein methylation (BPPM) has demonstrated its merits. In this approach, specific PMTs are engineered to process S-adenosyl-L-methionine (SAM) analogs as cofactor surrogates and label their substrates with distinct chemical modifications for target elucidation. Despite the proof-of-concept advancement of BPPM, few efforts have been made to explore its generality. With two cancer-relevant PMTs, EuHMT1 (GLP1/KMT1D) and EuHMT2 (G9a/KMT1C), as models, we defined the key structural features of engineered PMTs and matched SAM analogs that can render the orthogonal enzyme-cofactor pairs for efficient catalysis. Here we have demonstrated that the presence of sulfonium-β-sp(2) carbon and flexible, medium-sized sulfonium-δ-substituents are crucial for SAM analogs as BPPM reagents. The bulky cofactors can be accommodated by tailoring the conserved Y1211/Y1154 residues and nearby hydrophobic cavities of EuHMT1/2. Profiling proteome-wide substrates with BPPM allowed identification of >500 targets of EuHMT1/2 with representative targets validated using native EuHMT1/2 and SAM. This finding indicates that EuHMT1/2 may regulate many cellular events previously unrecognized to be modulated by methylation. The present work, therefore, paves the way to a broader application of the BPPM technology to profile methylomes of diverse PMTs and elucidate their downstream functions.

Targeting protein methylation: from chemical tools to precision medicines

Overview of the Development of Protein Arginine Methyltransferase Modulators: Achievements and Future Directions.

Protein arginine methylation: from enigmatic functions to therapeutic targeting

Defining Efficient Enzyme-Cofactor Pairs for Bioorthogonal Profiling of Protein Methylation

DNA Methyltransferases: Emerging Targets for the Discovery of Inhibitors As Potent Anticancer Drugs

Small Molecule Inhibitors of Protein Arginine Methyltransferases

DNA methyltransferase inhibitors in cancer: From pharmacology to translational studies

Protein arginine methyltransferases: promising targets for cancer therapy

Small molecules targeting selected histone methyltransferases (HMTs) for cancer treatment: Current progress and novel strategies

Methylation Across the Central Dogma in Health and Diseases: New Therapeutic Strategies

Protein Lysine Methyltransferases Inhibitors

Probes and Targets of DNA Methylation and Demethylation in Drug Development

Targeting DNA methyltransferases for cancer therapy

DNA Methylation Targeting: The DNMT/HMT Crosstalk Challenge

Targeted Protein Posttranslational Modifications by Chemically Induced Proximity for Cancer Therapy

Bioorthogonal Profiling of Protein Methylation Using Azido Derivative of S-adenosyl-L-methionine.

Chemical probes and methods for the study of protein arginine methylation

Technologies for Targeting DNA Methylation Modifications: Basic Mechanism and Potential Application in Cancer.

Natural bioactive compounds targeting DNA methyltransferase enzymes in cancer: Mechanisms insights and efficiencies

Targeting epigenetic regulators for cancer therapy: modulation of bromodomain proteins, methyltransferases, demethylases, and microRNAs

Targeting DNA Methylation Machinery in Pediatric Solid Tumors